Full Title
A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression >=50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression (SUNRAY-01)Purpose
Researchers are doing this study to see if giving LY3537982 with standard lung cancer drugs is safe and works well. The people in this study have non-small cell lung cancer that has spread. In addition, their cancers have a gene mutation (change) called KRASG12C, which can cause cancer cells to grow.
LY3537982 targets the KRASG12C mutation and prevents it from sending signals to cancer cells to grow and spread. It is taken orally (by mouth). If you join this study, you will also get pembrolizumab immunotherapy, pemetrexed, and carboplatin or cisplatin. These drugs are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have stage 4 non-small cell lung cancer with a KRASG12C mutation.
- Have not received any lung cancer treatment within 6 months of entering the study.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Kathryn Arbour’s office at 646-608-3792.